secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001171843-24-004721
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Q2 net loss narrows to $2.7M; cash $9.3M; clinical programs advance
------------------------------------------------------------------------

- Net loss Q2 2024 $2.7M ($0.07/sh) vs $6.2M ($0.18/sh) Q2 2023; 6-month loss $6.5M vs $11.9M.
- Cash $9.3M at Jun 30, up from $3.4M at Dec 31; cash used in ops $2.3M for Q2, reduced from $4.2M YoY.
- Closed $5.8M PIPE at 25% premium to new investor; cash runway extended into 2025.
- AgenT-797: Phase 2 gastric cancer advancing, early data at upcoming conference; Phase 1 GvHD activation planned; ARDS expanded access shows clinical benefit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000117184324004721/0001171843-24-004721-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000117184324004721/f8k_081324.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-004721

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer